- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cannabis Weekly Round-Up: New US Cannabis Bill Arrives, Path Forward Uncertain
A much-anticipated US cannabis reform bill was finally revealed in the Senate. Can it clear Congress?
A new piece of legislation geared at federal cannabis reform was introduced in the US Senate this week. However, experts aren’t confident that it will be approved by Congress.
Investors also saw a top analyst change their perspective on some cannabis companies in Canada.
Keep reading to find out more cannabis highlights from the past five days.
New cannabis reform bill gets Senate introduction
On Thursday (July 21), Senate Democrat leaders introduced the Cannabis Administration and Opportunity Act (CAOA), a new cannabis reform bill designed to remove cannabis from the Controlled Substances Act and eliminate doubt regarding the legality of state markets.
CAOA was designed by Senate majority leader Chuck Schumer (D-NY) with Finance Committee Chair Ron Wyden (D-OR) and Senator Cory Booker (D-NJ). The bill, if approved, would provide the first federal cannabis policy framework in the US, and would expunge federal cannabis-related records.
The US Food and Drug Administration and the Tobacco Tax and Trade Bureau would be tasked with regulating the industry. Aside from that, a federal excise tax on cannabis sales of between 5 and 25 percent would be introduced, according to the National Cannabis Industry Association (NCIA).
Aaron Smith, co-founder and CEO of the NCIA, said in an email statement that CAOA is a far-reaching and historic bill. However, he doesn't want the Senate to leave the SAFE Banking Act behind.
“(The SAFE Banking Act) would provide tangible and immediate relief to small businesses and improve public safety by opening access to banking and financial services in our industry,” Smith said.
Despite the excitement around CAOA, a Politico report shows that it stands little chance of clearing the Senate, and even if it did it’s not clear whether President Joe Biden would sign it into law as it stands.
In an email statement, Bethany Gomez, managing director of Brightfield Group, said CAOA's increased taxation would be “problematic for an industry that is already heavily taxed at the state and local levels.”
Even so, she said the announcement of CAOA gives hope to the industry that Congress is motivated to pass some kind of meaningful cannabis policy this year. “Hopes are high that banking and other incremental gains on cannabis will be made this year, even if the CAOA does not pass in its full form,” Gomez said.
She added that this bill could unlock interstate commerce opportunities, “which would completely upend the competitive landscape, company valuations and eliminate many jobs in cultivation and processing facilities.”
An analyst with a boutique banking firm that’s heavily invested in the cannabis market issued a note to investors when the bill was still just rumored, saying investors shouldn’t get their hopes up too much.
“With the November mid-term elections only four months away (where Democrats are likely to lose ground), we believe the prospect of such a landmark bill getting to the finish line in the current legislative session is extremely remote,” Canaccord Genuity's Matt Bottomley said, according to BNN Bloomberg.
Cowen analyst adjusts views on Canadian cannabis names
Financial services firm Cowen shared a new perspective on its expectations for cannabis companies in Canada, as per a report from BNN Bloomberg.
In a new report, Vivien Azer, a Cowen analyst covering cannabis, told clients that the industry's 21 percent sales growth in Q2 was down 2 percent compared to Q2 2021.
The decline, however, represents progress compared to dragging results in recent quarters.
Azer said the Canadian cannabis market still is “highly competitive and fragmented.”
Among her stock evaluation changes, the analyst trimmed her 12 month price expectation for shares of Canopy Growth (NASDAQ:CGC,TSX:WEED) from C$6.50 to C$3.40.
Cannabis company news
- TerrAscend (CSE:TER,OTCQX:TRSSF)announced the opening of its first New Jersey storefront in partnership with edibles brand Cookies. Two more locations are planned for later this year. "New Jersey rec is off to a strong start, and we are thrilled to add the exclusive Cookies Corners shopping experience to our dispensaries," Jason Wild, executive chairman of TerrAscend, said.
- High Tide (NASDAQ:HITI,TSXV:HITI)closed a bought-deal offering worth nearly 5 million units of the company for gross proceeds of C$11.5 million. “The net proceeds of the Offering will be used for constructing and opening new retail cannabis store locations, the repayment of debt and for general corporate and working capital purposes,” the company said.
- Flora Growth (NASDAQ:FLGC)held a meeting with Gustavo Bolivar, the Colombian senator behind a new legalization bill in the nation. “We are honored to work closely with Sen. Bolivar and other key policymakers to support legislation that will provide safe access to cannabinoid-based products both domestically and in international markets,” Chairman and CEO Luis Merchan said.
- Canopy Growthannounced the closing of an exchange transaction to reduce its debt obligations by approximately C$263 million. "We continue to assess all available options to further optimize our balance sheet and address the remaining 4.25% unsecured notes in advance of their maturity to ensure Canopy Growth is well positioned to continue investing in the highest potential areas of our business to drive future growth," Judy Hong, CFO at Canopy Growth, said.
Don't forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
The Beginner’s Guide to Investing in Biotech
Ready to invest in biotech? Our beginner's guide makes it simple to get started.
Download your investing guide today.
Learn About Exciting Investing Opportunities in the Biotech Sector
Your Newsletter Preferences
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.
Learn about our editorial policies.